[{"data":1,"prerenderedAt":181},["ShallowReactive",2],{"drug-degarelix":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":74,"warnings":84,"renal":92,"monitoring":93,"interactions":94,"review":95,"examples":98,"atc":107,"iran":109,"usApproval":116,"links":122,"populations":137},"degarelix",1,{"fa":7,"en":8},"دگارلیکس","Degarelix","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتاگونیست GnRH","GnRH antagonist",[14],{"name":15,"market":16},"Firmagon","US",[18,19,7],"firmagon","فیرماگون",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"vial-120","powder-for-injection","sc","120 mg vial (starting dose = 2 vials)",{"amount":27,"unit":28,"perUnit":29},120,"mg","vial",[16],[32],{"source":33,"section":34},"fda-firmagon","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"vial-80","80 mg vial (maintenance)",{"amount":39,"unit":28,"perUnit":29},80,[16],[42],{"source":33,"section":34},[44,62],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":57,"durationDays":60,"allowedFormulations":61},"start","prostate-cancer",{"fa":48,"en":49},"سرطان پیشرفته پروستات — شروع ۲۴۰ mg (دو تزریق ۱۲۰ mg زیرجلد شکم)","Advanced prostate cancer — start 240 mg (two 120 mg SC abdominal injections)",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":56,"dosesPerDay":5},240,[58],{"source":33,"section":59},"2.1",{"min":5,"max":5},[22],{"id":63,"disease":46,"label":64,"population":67,"type":54,"unit":28,"dose":69,"refs":70,"durationDays":72,"allowedFormulations":73},"maint",{"fa":65,"en":66},"نگهدارنده — ۸۰ mg زیرجلد هر ۲۸ روز (اولین ۲۸ روز پس از شروع)","Maintenance — 80 mg SC every 28 days (first 28 days after the starting dose)",{"minAge":68},{"value":52,"unit":53},{"perDose":39,"dosesPerDay":5},[71],{"source":33,"section":59},{"min":5,"max":5},[36],[75],{"id":76,"severity":77,"text":78,"refs":81},"hyper","block",{"fa":79,"en":80},"سابقه حساسیت شدید به دگارلیکس.","History of severe hypersensitivity to degarelix.",[82],{"source":33,"section":83},"4",[85],{"text":86,"refs":89},{"fa":87,"en":88},"واکنش حساسیتی؛ طولانی شدن QT؛ سمیت جنینی.","Hypersensitivity reactions; QT prolongation; embryo-fetal toxicity.",[90],{"source":33,"section":91},"5",[],[],[],{"status":96,"reviewer":97,"date":97},"unverified",null,[99,104],{"regimen":45,"formulation":22,"input":100,"expect":103},{"ageYears":101,"weightKg":102},70,75,{"perDose":56},{"regimen":63,"formulation":36,"input":105,"expect":106},{"ageYears":101,"weightKg":102},{"perDose":39},[108],"L02BX02",{"status":110,"refs":111},"not-found",[112],{"source":113,"section":114,"url":115},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Degarelix",{"kind":117,"refs":118,"id":121},"NDA",[119],{"source":33,"section":120},"SPL approval \u002F marketing category","NDA022201",[123,126,130,134],{"kind":124,"url":125,"label":121},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022201",{"kind":127,"url":128,"label":129},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b","FDA Firmagon",{"kind":131,"url":132,"label":133},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609022.html","Degarelix Injection",{"kind":135,"url":136,"label":108},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L02BX02",{"pregnancy":138,"lactation":147,"pediatric":156,"geriatric":165,"reproductive":173},{"level":139,"text":140,"quote":143,"refs":144},"avoid",{"fa":141,"en":142},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Based on findings in animal studies and mechanism of action, FIRMAGON can cause fetal harm and loss of pregnancy when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ].",[145],{"source":33,"section":146},"8.1",{"level":148,"text":149,"quote":152,"refs":153},"caution",{"fa":150,"en":151},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","The safety and efficacy of FIRMAGON have not been established in females.",[154],{"source":33,"section":155},"8.2",{"level":157,"text":158,"quote":161,"refs":162},"not-established",{"fa":159,"en":160},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[163],{"source":33,"section":164},"8.4",{"level":148,"text":166,"quote":169,"refs":170},{"fa":167,"en":168},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of subjects in clinical studies of FIRMAGON, 82% were age 65 and over, while 42% were age 75 and over.",[171],{"source":33,"section":172},"8.5",{"level":148,"text":174,"quote":177,"refs":178},{"fa":175,"en":176},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Infertility Based on findings in animals and mechanism of action, degarelix may impair fertility in males and females of reproductive potential [see Nonclinical Toxicology (13.1) ].",[179],{"source":33,"section":180},"8.3",1792191536480]